Vivos Therapeutics, Inc.VVOSNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank85
5Y CAGR+30.1%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+30.1%/yr
Long-term compound
Percentile
P85
Within normal range
vs 5Y Ago
3.7x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 24.26% |
| Q2 2025 | 27.03% |
| Q1 2025 | 10.32% |
| Q4 2024 | -1.53% |
| Q3 2024 | 8.80% |
| Q2 2024 | -20.34% |
| Q1 2024 | -8.18% |
| Q4 2023 | 15.96% |
| Q3 2023 | -19.02% |
| Q2 2023 | -9.77% |
| Q1 2023 | -13.42% |
| Q4 2022 | 7.12% |
| Q3 2022 | -17.70% |
| Q2 2022 | 4.01% |
| Q1 2022 | -4.36% |
| Q4 2021 | 11.14% |
| Q3 2021 | 13.38% |
| Q2 2021 | 26.55% |
| Q1 2021 | 9.06% |
| Q4 2020 | 28.59% |
| Q3 2020 | 6.50% |
| Q2 2020 | -17.31% |
| Q1 2020 | 5.61% |
| Q4 2019 | -16.42% |
| Q3 2019 | 27.53% |
| Q2 2019 | -0.00% |
| Q1 2019 | 0.00% |